VRTX
Vertex Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
5.32 / 10
Netural
The fund flow profile scores 7.73/10, demonstrating robust fund flow characteristics. Favorable Small, Medium, and Large movements are tempered by challenging overall, block, and Extra-large dynamics, supporting positive flow assessment. Analyst consensus points to overwhelmingly bullish analyst consensus with strong conviction. Distribution analysis: Strong Buy(20.0%), Buy(80.0%) among 5 research opinions, supported by 2.90 historical weighted rating.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
20%
Buy
80%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-22
InstitutionRBC Capital
Times predicted8
Historical Win Rate75.0%
Is money flowing into or out of VRTX?
- VRTX holds a Bearish analyst rating, with 80% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 5.32/10 (Netural).
